Clinical trial · Observational
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
BARC: A Secreted Marker of Kidney Cancer
NCT00900276CI-TRIAL-00033627completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in patients with kidney cancer or cancer of the urothelium and in healthy participants.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Transitional Cell Cancer of the Renal Pelvis and Ureter | — | UNRESOLVED | — |
| Urethral Cancer | Malignant Urethral Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunologic technique | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| mass spectrometry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Presence of bone morphogenetic protein antagonist regulated in cancer (BARC) in urine and serum samples
- measure
- BARC expression levels
- measure
- Correlation of changes in serum markers of iron metabolism with changes in BARC expression
- measure
- Feasibility of an enzyme-linked immunosorbent assay to detect BARC levels as a diagnostic procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion:
* Age \> 18 years
* Meets 1 of the following criteria:
* Diagnosis of renal cell carcinoma, meeting all of the following criteria:
* Suitable surgical candidate
* No clinical or pathologic T stage \> T2
* No clinical or pathologic evidence of vein and/or lymph node involvement
* No evidence of metastatic disease as evaluated by abdominal/pelvic CT scan or MRI, chest x-ray or chest CT scan, and bone scan (if alkaline phosphatase abnormal)
* Diagnosis of transitional cell carcinoma of the urothelium
* Currently undergoing Bacille calmette-guérin (BCG) therapy OR has not received prior BCG therapy
* Healthy participant (control)
* No history of carcinoma
Exclusion:
* Previous or concurrent malignancy except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer
* Serious medical or psychiatric illness that would preclude study compliance
* Current participation in a treatment related research study within the last 30 days
* Acute illness
* Bleeding disorder or dyscrasiaReferences
Publications (0)
Data not yet available
No reference posted for this study.